Could haemophilia be 'cured' by a new gene therapy that costs £2.5million per jab?

Could haemophilia be 'cured' by a new gene therapy that costs £2.5million per jab? A genetic drug hailed as 'close to a cure' for the deadly bleeding disorder haemophilia has been given the green light by European health watchdogs.

In trials, a single jab of Roctavian left nine in ten patients symptom-free and no longer in need of the daily injections usually required to control their condition.

Last week the European Medicines Agency, the equivalent of the UK's Medicines and Healthcare Products Regulatory Agency, approved the treatment, opening the door for its widespread use here. The Daily Mail